Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to 0.55%.

  • Nurix Therapeutics' Return on Capital Employed fell 1200.0% to 0.55% in Q4 2025 from the same period last year, while for Nov 2025 it was 0.55%, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of 0.48% for FY2025, which is 300.0% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Return on Capital Employed is 0.55%, which was down 1200.0% from 0.56% recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Return on Capital Employed registered a high of 0.22% during Q2 2021, and its lowest value of 0.64% during Q1 2024.
  • Over the past 5 years, Nurix Therapeutics' median Return on Capital Employed value was 0.47% (recorded in 2022), while the average stood at 0.46%.
  • Per our database at Business Quant, Nurix Therapeutics' Return on Capital Employed crashed by -2600bps in 2022 and then soared by 2200bps in 2025.
  • Over the past 5 years, Nurix Therapeutics' Return on Capital Employed (Quarter) stood at 0.28% in 2021, then plummeted by -78bps to 0.5% in 2022, then decreased by -26bps to 0.63% in 2023, then surged by 32bps to 0.43% in 2024, then decreased by -28bps to 0.55% in 2025.
  • Its Return on Capital Employed stands at 0.55% for Q4 2025, versus 0.56% for Q3 2025 and 0.44% for Q2 2025.